Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed adenocarcinoma of the prostate
• Disease progression following androgen ablation therapy (hormonal or surgical) by either:
• * Increase in the product of bidimensional diameters of 1 or more radiographically documented sites of measurable disease OR
• * Two consecutive increases in PSA documented over a previous reference value
• * First increase in PSA should occur a minimum of 1 week from the reference value and be confirmed
• * First PSA value is less than the previous value, then patient is eligible provided next PSA is greater than the second PSA
• Testosterone levels documented in the castrate range (i.e., less than 30 ng/mL)
• PATIENT CHARACTERISTICS:
• Age:
• 18 to 85
• Performance status:
• CALGB 0-2
• Life expectancy:
• Not specified
• Hematopoietic:
• WBC at least 3,000/mm3
• Platelet count at least 100,000/mm3
• Hepatic:
• Bilirubin normal
• SGOT no greater than 2.5 times upper limit of normal (ULN) if alkaline phosphatase normal OR
• Alkaline phosphatase no greater than 4 times ULN if SGOT normal OR
• SGOT no greater than 1.5 times ULN and alkaline phosphatase no greater than 2.5 times ULN
• Renal:
• Creatinine no greater than 2.0 mg/dL
• Cardiovascular:
• No myocardial infarction within past year
• No significant change in anginal pattern within past 6 months
• No New York Heart Association class II-IV heart disease
• No deep venous thrombosis within past year
• Other:
• No significant peripheral neuropathy
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• Prior chemotherapy allowed except taxanes or platinum derivatives
• Endocrine therapy:
• See Disease Characteristics
• At least 4 weeks since prior antiandrogens
• Radiotherapy:
• At least 4 weeks since prior radiotherapy
• Surgery:
• See Disease Characteristics